Replies to post #159074 on Biotech Values

[genisi]

The Teva-Lonza FoB collaboration announced in 2009 (#msg-34930012) appears to be dead, for all practical purposes

After the discontinuation of TL011 (the JV's Rituxan knockoff) phase III in Oct 2012, and the hardly mentioned FoB program on Teva's analyst day in Dec 2012, it's not surprising.

[jbog]

Teva and Lonza announce decision to discontinue biologics joint venture

Teva Pharmaceutical and Lonza Group announced that following a strategic review of the Teva-Lonza Joint Venture, the companies have decided to discontinue their collaboration for the development, manufacturing and marketing of biosimilars. The companies said that the discontinuation of the TL-JV will enable both companies to better advance their own strategies and efforts in serving those healthcare communities. Both companies said they will continue to explore opportunities to maximize the value of the investments and progress that the joint venture has made to this point, and remain in agreement that affordable, efficacious and safe biosimilar treatments will bring benefits to patients and better serve these communities.